MyelinWatch EL
← Back to updates
Emerging treatmentsMyelin repair
Preparing for first human studiesAnnounced or plannedNo evidence of benefit in people yet

Preparing for human testing

Low-dose theophylline patch receives funding to prepare for its first study in people

Worth knowing

Claire Jacob's team at Johannes Gutenberg University Mainz announced €1.1 million to improve the skin patch, manufacture it to pharmaceutical standards and prepare a first safety study in healthy volunteers.

What this means for people with MS

The funding brings the patch closer to human testing, but the first study is not yet publicly registered and there is no evidence of benefit in people with MS.

What kind of evidence exists?
Not yet tested in people • development work
How reliable is this source?
Official university update and a scientific paper about the patch formulation

Related study or programme: Low-dose theophylline patch →

University / investigatorRead the source ↗

Related substantive developments

Myelin repair
Laboratory or animal researchLaboratory or animal programmePromising early finding

Laboratory and animal research

Blocking fibronectin restored remyelination in experimental models

A PNAS study found that a protein called fibronectin can build up in areas where myelin has been lost. This may trap immature cells that could otherwise become myelin-making cells. Blocking fibronectin improved myelin repair and symptoms in two animal models.

Read the update →Peer-reviewed paper
Emerging treatmentsMyelin repair
Registered study in peopleOngoing, but not accepting participantsNo evidence of benefit in people yet

Phase 3 study that can add or remove treatments

OCTOPUS: the first review of metformin and alpha-lipoic acid is planned for September 2026

The first OCTOPUS review in progressive MS will assess metformin and alpha-lipoic acid. It will look at brain shrinkage on MRI, disability, walking speed and hand function.

Read the update →University / investigator
Emerging treatmentsMyelin repair
Planned study in peopleAnnounced or plannedPermission or regulatory step

Planned Phase 2 study

Lucid-MS: the FDA removed its temporary pause, allowing a planned Phase 2 study to move forward

After an earlier temporary pause, the FDA allowed Lucid-MS to move forward. The company plans a Phase 2 study in progressive MS in which participants will be randomly assigned Lucid-21-302 or an inactive placebo, without knowing which one they receive.

Read the update →Official company filing